ROME, February 8, 2011 /PRNewswire/ --
- CID to Update Interventional Cardiologists on Cre8(TM) Drug Eluting Stent at the 2011 Joint Interventional Meeting
CID spa, a European company leader in interventional medicine, will present the key technologies implemented on CID's Cre8(TM) DES as well as all the new preclinical data at the Joint Interventional Meeting (JIM) during the Lunch Symposium "NEW DES: A NEW STEP FORWARD?" on Thursday, February 10, 2011.
Alexandre Abizaid, MD, PhD., Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo, Brazil, in his presentation "New CID Polymer Free Reservoirs and Bio-inducer DES" will point out the unique features of the Cre8(TM) DES. The unique polymer-free Abluminal Reservoir Technology (ART) together with the new Amphilimus(TM) formulation allows a controlled and targeted drug elution to the vessel wall. The iCarbofilm bio-inducer surface has been developed to lower the risk of thrombotic events and to avoid the need for prolonged dual antiplatelet therapy.
Didier Carrie, MD, PhD, Head of Hemodynamics and Angioplasty at Toulouse Teaching Hospital and Vice-Dean of the Faculty of Medicine in the "Cre8(TM): Preclinical Experience and Clinical Plan" presentation will review all the pre-clinical data on Cre8(TM). Prof. Carrie will also outline the design of the randomized clinical study "NEXT", the results of which will be presented at European PCR 2011.
Commenting on the innovative technology in its new Cre8(TM) DES, Franco Vallana, Chief Executive Officer of CID s.p.a. said: "As we move closer to launching our newest stent, it is important that cardiologists from around the world are kept up to date on our innovative technologies with Cre8. The total elimination of polymers, thanks to our Abluminal Reservoir Technology (ART), and the use of a bio-inducer Carbon-coated surface, will certainly benefit physicians and their patients."